Kognitivni fenotip kod Neurofibromatoze tip 1

  • Jelena Todorović specijalista defektolog, Dom zdravlja Zvečan
  • Dragan Pavlović Profesor, Fakultet za specijalnu edukaciju i rehabilitaciju, Beograd
  • Mirna Zelić Logoped, Zavod za psihofiziolo[ke poreme'aje i govornu patologiju "prof.dr Cvetko Brajovic", Beograd
  • Lana Jerkić Logoped, Doktorand na Fakultetu za specijalnu edukaciju i rehabilitaciju, Beograd

Abstract


Neurofibromatoses are a set of different genetic disorders that have a common characteristic of the appearance of nervous system tumors. There are three forms of the disease, of which type 1  neurofibromatosis (NF 1) is the most common. NF 1 is an inherited autosomal-dominant disease, with a high rate of new mutations. In addition to the many physical manifestations and complications that occur in persons with NF 1, there are also numerous cognitive difficulties, including lower general intellectual functioning, learning difficulties, but also problems in attention, visual abilities, executive functions, and speech. Attention disorders are up to three times more common in people with NF 1, while learning disabilities are present in more than half of these subjects. Disturbances in the field of
visuospatial perception are recognizable even in the preschool period. About 80% of children with NF1 exhibit
various speech and language disorders: slow early speech development, slower vocabulary enrichment, syntactic, semantic, and phonological speech disorders. Disruption of executive functions will manifest itself in the areas of working memory, organization, planning/problem-solving. This will reflect as the underperformance in academic achievement. Nearly one-third of these persons have emotional
and social problems.

References

Bogdanovic R, Radlovic N. Pedijatrija. In: Dimitrijevic N, editor. Neurokutani sindromi. Beograd 2016. p.1340-43.

Sabol Z, Sabol F. Neurofibromatoza tipa 1 – od kliničke i genetske dijagnoze do otkrivanja komplikacija i lečenja. Medix. 2009;15:238-47.

Sampson J, Thompson H, Parilo D. Caring for children with neurofibromatosis type 1. Nursing. 2019;49(4):30-6.

Heimgärtner M, Granström S, Haas-Lude K, Leark R, Mautner VF, Lidzba K. Attention Deficit Predicts Intellectual Functioning in Children with Neurofibromatosis Type 1. International Journal of Pediatrics. 2019:1-10.

Jouhilahti E-M, Visnapuu V, Soukka T et al. Oral soft tissue alterations in patient with neurofibromatosis. Clinical Oral Investigations. 2012;16:551-8.

Bongiorno MR, Pistone G, Arico M. Manifestation of the tongue in Neurofibromatosis type 1. Oral Diseases. 2006;12:125-9.

Cunha KS, Rozza-de-Menezes RE, Luna EB et al. High prevalence of hyposalivation in individuals with neurofibromatosis 1: a case-control study. Orphanet. J Rare Dis. 2015; 10:24.

Villa A, Connell CL, Abati S. Diagnosis and managment of xerostomia and hyposalivation. Therapeutics and Clinical Risk Management. 2014;11:45-51.

Pannier S. Congenital pseudoarthrosis of the tibia. Orthopaedics & Traumatology Surgery & Research. 2011;91:97 750-61.

Serdaroglu E, Konuskan B, Oguz KK, Gurler G, Yalnizoglu D, Anlar B. Epilepsy in neurofibromtosis type 1: Diffuse cerebral dysfunction. Epilepsy & Behavior.2019;98:6-9.

North KN. Neurofibromatosis 1 in childhood. Seminars in Pediatric Neurology. 1998;5:231-42.

Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Research. 2002;62:1573-7.

Bogadi M, Keštelan S, Bakija I, Kasun B. Psyhiatric disorders in patients with neurofibromatosis. Libri Oncologi. 2018;46(2-3):105-112.

Vaucheret Paz E, Lopez Ballent A, Puga C, Garcia Basalo MJ, Baliarda F, Ekonen C, et al. Cognitive profile and disorders affecting higher brain functions in paediatric patients with neurofibromatosis type 1. Neurologia. 2019;34:353-9.

Myers M, Maddigan A, Santa Maria M. Neurological and neuropsychiatric disorders: other. Archives of Clinical Neuropsychology. 2019;34:860-1099.

Torres Nupan MM, Velez Van Meerbeke A, Lopez Cabra CA, Herrera Gomez PM. Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. Frontiers in Pediatrics. 2017;227(5):1-18.

Isenberg JC, Templer A, Gao F, Titus JB, Gutmann DH. Attention skills in children with Neurofibromatosis Type 1. Journal of child neurology. 2013;28:45-9.

Krab LC, Aarsen FK, de Goede-Bolder A, Catsman-Berrevoets CE, Arts WF, Moll HA, et.al. Impact of neurofibromatosis type 1 on school performance. Journal of child neurology. 2008;23:1002-10.

Beaussart ML, Barbarot S, Mauger C, Roy, A. Systematic Review and Meta-analysis of Executive Functions in Preschool and School-Age Children With Neurofibromatosis Type 1. Journal of the International Neuropsychological Society. 2018;24:977-994.

Hyman Sl, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology. 2005; 65:1037-44.

Hyman Sl, Shores A, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile and atention-deficit-hyperactivity disorder. Developmental medicine and child neurology. 2006;48:973-7.

North K, Hyman S, Barton B. Review Article: Cognitive deficits in neurofibromatosis 1. Journal of child neurology. 2002;17:605-12.

Lehtonen A, Howie E, Trump D, Husom SM. Behaviour in children with neurofibromatosis type 1:cognition, executove function, attention, emotion, and social competence: Review. Developmental Medicine & Child Neurology. 2013;55:111-25.

Pardej S, Lee K, Yund B, Casnar C, Klein-Tasman B. An Investigation of the Use of Computerized Attention/Executive Functioning Measures with School Age Children with Neurofibromatosis Type 1. Poster prezentovan: The Gatlinburg Conference on Research and Theory in Intellectual and Developmental Disabilities. 2020; San Diego, California.

Baudou E, Nemmi F, Biotteau M, Maziero S, Peran P, Chaix Y. Can the Cognitive Phenotype in Neurofibromatosis Type 1 (NF1) Be Explained by Neuroimaging? A Review. Frontiers in Neurology. 2020;10:1373.

Lorenzo J, Barton B, Arnold SS, North KN. Cognitive features that distinguish preschool-age children with neurofibromatosis type 1 from their peers: A matched case-control study. The Journal of Pediatrics. 2013;163:1479-83.

Cosyns M, Mortier G, Janssens S, Bogaert F, D'Hondt S, Van Borsel J. Articulation in schoolchildren and adults with neurofibromatosis type 1. Journal of Communications Disorders. 2012;45(2).111-20.

Barton B, North K. Social skills of children with neurofibromatosis type 1. Developmental medicine and child neurology. 2004;46:553-63.

Dembitz A, Sabol Z. Komunikacijske poteškoće kod osoba oboljelih od neurofibromatoze. Istraživanja na području defektologije 1992:117-21.

Oostenbrink R, Spong, de Goede-Bolder A, Landgraf JM, Raat H, Moll HA. Parental reports of health-related quality of life in young children with neurofibromatosis type 1: influence of condition specific determainants. Journal of Pediatrics. 2017;151:182-186.

Wessel LE, Gao F, Gutmann DH, Dunn CM. Longitudinal analysis of developmental delays in children with neurofibromatosis type 1. Journal of Child Neurology. 2013;28(12):1689-93.

Rietman AB, Van der Vaart T, Plasschaert E, Nicholson B, Oostenbrink R, Krab L, et al. Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1. American Journal of Medical Genetics. 2017;1-10.

Rietman AB, Van der Vaart T, Plasschaert E, Nicholson B, Oostenbrink R, Krab L, et al. Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1. American Journal of Medical Genetics. 2017;1-10.

Eby NS, Griffith JL, Gutmann DH, Morris SM. Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior and magnetic resonance imaging. Developmental Medicine & Child Neurology. 2019;61:972-978.

Spuijbroek At, Oostenbrink R, Landgraf JM, Rietveld E, de Goede-Bolder A, van Beeck EF et al. Health-related quality of life in preschool children in five health condition. Quality Life Research. 2011;20:779-86.

Krab LC, Oostenbrink R, de Goede-Bolder A, Aarsen FK, Elgersma Y, Moll HA. Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior. Journal of Pediatrics. 2009;154:420-425.

Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. Journal of Neurooncology. 2013;114:257-262.

Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, et al. Emotional finctioning of patient with neurofibromatosis tumor suppressor syndrome. Genet. Med. Off. J.Am. Coll.Med.Genet. 2012;14:977-82.

Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handbook of Clinical Neurology. 2018;148:799-811.

Chisholm AK, Anderson VA, Pride NA, Malarbi S, North KN, Payne JM. Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis. Neuropsychology Review. 2018;28(3):317-40.

Kang E, Kim YM, Seo GH, Oh A, Yoon HM, Ra YS et al. Phenotype categorization of neurofibromatosis type 1 and correlation to NF1 mutation types. Journal of Human Genetics. 2020;65:79-89.

Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Medical Clinics of North America. 2019;103(6);1035-1054.

Hou Y, Allen T, Wolters P, Toledo-Tamula M, Martin S, Baldwin A et al. Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas. Developmental Medicine & Child Neurology. 2020. doi:10.1111/dmcn.14489.

Published
2021/01/09
How to Cite
Todorović, J., Pavlović, D., Zelić, M., & Jerkić, L. (2021). Kognitivni fenotip kod Neurofibromatoze tip 1. Engrami, 42(2). https://doi.org/10.5937/engrami41-28271
Section
PROFESSIONAL ARTICLE